Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube

NCT05538624 is registered in ClinicalTrials.gov with Avenge Bio, Inc as lead sponsor.

NCT NCT05538624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05538624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube
Lead sponsor
Avenge Bio, Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
December 9, 2022
Completion date
April 10, 2024
Enrollment
14 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma ovary, fallopian tube cancer, high grade serous adenocarcinoma, neoplasm, ovarian, primary peritoneal carcinoma, primary peritoneal cavity cancer, serous adenocarcinoma of ovary, serous adenocarcinoma of primary peritoneum